Cargando…

Galectin-1 dimers can scaffold Raf-effectors to increase H-ras nanoclustering

Galectin-1 (Gal-1) dimers crosslink carbohydrates on cell surface receptors. Carbohydrate-derived inhibitors have been developed for cancer treatment. Intracellularly, Gal-1 was suggested to interact with the farnesylated C-terminus of Ras thus specifically stabilizing GTP-H-ras nanoscale signalling...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blaževitš, Olga, Mideksa, Yonatan G., Šolman, Maja, Ligabue, Alessio, Ariotti, Nicholas, Nakhaeizadeh, Hossein, Fansa, Eyad K., Papageorgiou, Anastassios C., Wittinghofer, Alfred, Ahmadian, Mohammad R., Abankwa, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834570/ https://www.ncbi.nlm.nih.gov/pubmed/27087647 http://dx.doi.org/10.1038/srep24165

Ejemplares similares

Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation
por: Šolman, Maja, et al.
Publicado: (2015)

The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions
por: Nakhaeizadeh, Hossein, et al.
Publicado: (2016)

ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold
por: Posada, Itziar M. D., et al.
Publicado: (2016)

Elaiophylin Is a Potent Hsp90/ Cdc37 Protein Interface Inhibitor with K-Ras Nanocluster Selectivity
por: Siddiqui, Farid A., et al.
Publicado: (2021)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

PDE6δ-mediated sorting of INPP5E into the cilium is determined by cargo-carrier affinity
por: Fansa, Eyad Kalawy, et al.
Publicado: (2016)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

Targeting the Raf kinases in human cancer: the Raf dimer dilemma
por: Durrant, David E, et al.
Publicado: (2018)

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
por: Jones, Greg G., et al.
Publicado: (2019)

Lipid Profiles of RAS Nanoclusters Regulate RAS Function
por: Zhou, Yong, et al.
Publicado: (2021)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

New mechanistic insights into the RAS-SIN1 interaction at the membrane
por: Pudewell, Silke, et al.
Publicado: (2022)

The mechanism of Raf activation through dimerization
por: Zhang, Mingzhen, et al.
Publicado: (2021)

Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner
por: Posada, Itziar M.D., et al.
Publicado: (2017)

Mechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again
por: Abankwa, Daniel, et al.
Publicado: (2020)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
por: Tran, Timothy H., et al.
Publicado: (2021)

Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain
por: Travers, Timothy, et al.
Publicado: (2018)

Inhibition of RAF dimers: it takes two to tango
por: Cook, Frazer A., et al.
Publicado: (2021)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Crystal Structure Reveals the Full Ras–Raf Interface and Advances Mechanistic Understanding of Raf Activation
por: Cookis, Trinity, et al.
Publicado: (2021)

Promotion of cancer cell stemness by Ras
por: Chippalkatti, Rohan, et al.
Publicado: (2021)

The Ras dimer structure
por: Rudack, Till, et al.
Publicado: (2021)

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS
por: Ilter, Metehan, et al.
Publicado: (2022)

Development of Highly Sensitive Biosensors of RAF Dimerization in Cells
por: Miyamoto, Kyoko, et al.
Publicado: (2019)

An engineered protein antagonist of K-Ras/B-Raf interaction
por: Kauke, Monique J., et al.
Publicado: (2017)

Does Ras Activate Raf and PI3K Allosterically?
por: Nussinov, Ruth, et al.
Publicado: (2019)

Cryo-EM structure of a RAS/RAF recruitment complex
por: Park, Eunyoung, et al.
Publicado: (2023)

Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis
por: Barkan, Batya, et al.
Publicado: (2013)

Interactome dynamics of RAF1-BRAF kinase monomers and dimers
por: Iglesias-Martinez, Luis F., et al.
Publicado: (2023)

Biophysical Mechanism for Ras-Nanocluster Formation and Signaling in Plasma Membrane
por: Gurry, Thomas, et al.
Publicado: (2009)

RAS Nanoclusters: Dynamic Signaling Platforms Amenable to Therapeutic Intervention
por: Van, Que N., et al.
Publicado: (2021)

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2018)

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis
por: Fritsche-Guenther, Raphaela, et al.
Publicado: (2016)

Role of autophagy in K-RAS- and B-RAF-driven lung cancers
por: White, Eileen
Publicado: (2014)

T cell leukemia control via Ras-Raf pathway inhibition with peptides
por: Marin, G, et al.
Publicado: (2017)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling
por: Nolan, Aoife A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g15rd8q6gld3shmkupkv1682ve